French medtech startup Tissium has raised €30 million in equity and secured up to €30 million in debt financing. The company develops “biomorphic programmable polymers” — adhesive materials that bind tissue and nerves without invasive stitches, reducing trauma and improving recovery. Its technology treats heart defects, hernias, and nerve damage, with two FDA-approved products. The Series D-2 round was led by an undisclosed US family-owned institutional investor, with debt provided by the European Investment Bank. Tissium has now raised €200 million in total equity. Funds will support US commercial expansion and further clinical trials.
In-Depth:
A French startup which applys a novel technology to reconstruct damaged tissue and restore it to its natural state has raised €30m in equity and taken out up to €30m in debt financing, it declared today.
Tissium has developed materials called ”biomorphic programmable polymers” that act as an adhesive, which bind nerves toreceiveher inside tissue, circumventing the required for invasive stitches. Its goal is to reduce trauma to the surrounding tissue and improve recovery rates in patients.
Tissium’s technology is applyd to repair heart defects, hernias, and damaged nerves. Two of its products- one for nerve repair, one for hernia treatment- have received approval by the US Food and Drug Administration (FDA). Tissium declared the €30m equity Series D-2 investment round was led by an undisclosed new US -based family-owned institutional investor.
The round has also been supported by new family offices, high net worth individuals and existing investors, it declared. Existing investors include Mérieux Développement and Cathay. Tissium has raised €200m in equity funding in total. The debt facility of up to €30m is from the European Investment Bank.
The funding will be applyd to finance the rolling out of its tech in the US, and fund clinical trials as it views to expand the tech to other areas of healthcare.
Christophe Bancel, CEO and co-founder, Tissium, declared: “We are now executing on our transition into a commercial-stage MedTech company while continuing to advance a differentiated pipeline built on the same underlying biomorphic polymer platform.”
